CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY

EHA Library, Evangelos Terpos, 215588

PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM’S MACROGLOBULINEMIA

EHA Library, Antonio Sacco, 215589

EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS

EHA Library, Joan Ballesteros, 215590

ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL

EHA Library, Matthew Jenner, 215591

POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE

EHA Library, David S. Siegel, 215592

DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)

EHA Library, Sara Bringhen, 215593

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN CASE OF SUBOPTIMAL RESPONSE TO POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS OF THE GMMG-PERSPECTIVE TRIAL

EHA Library, Katja Weisel, 215594

SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS

EHA Library, Rowan Kuiper, 215595

CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)

EHA Library, Chandramouli Nagarajan, 215596

WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY

EHA Library, Noa Biran, 215597

EXTENDED 5-Y FOLLOW-UP OF PHASE 3 ELOQUENT-2 STUDY: ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 215598

LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.

EHA Library, Francesca Gay, 215599

A GLOBAL TREATMENT STANDARD IN MULTIPLE MYELOMA (MM) REMAINS ELUSIVE DESPITE ADVANCES IN CARE OVER 15 YEARS: FIRST RESULTS FROM INSIGHT MM, THE LARGEST GLOBAL PROSPECTIVE, OBSERVATIONAL MM STUDY

EHA Library, Mario Boccadoro, 215600

TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015

EHA Library, Avinash Dinmohamed, 215601

NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: DATA FROM A PHASE II TRIAL OF POMALIDOMIDE PLUS DEXAMETHASONE

EHA Library, Katja Weisel, 215602

REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY

EHA Library, Yoshiaki Abe, 215603

EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS

EHA Library, Ioannis Kostopoulos, 215604

EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS

EHA Library, Gregory Kaufman, 215605

EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.

EHA Library, ANA PILAR GONZALEZ RODRIGUEZ, 215606

CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY

EHA Library, Ravi Vij, 215607

COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015

EHA Library, Annette Vangsted, 215608

OVERALL SURVIVAL OF PATIENTS POST-TRANSPLANT: STUDY RESULTS FROM TWO PHASE 3 TRIALS ASPIRE AND ENDEAVOR

EHA Library, Hartmut Goldschmidt, 215609

DURABLE PROGRESSION-FREE SURVIVAL BENEFIT IN EARLY RESPONDERS TO ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF 4-YEAR DATA FROM ELOQUENT-2

EHA Library, CHRISTOF SCHEID, 215610

SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA

EHA Library, Marcella Tschautscher, 215611

NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY

EHA Library, Mauricette Michallet, 215612

REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT

EHA Library, Faouzi Djebbari, 215613

BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME

EHA Library, Luis Gerardo Rodríguez-Lobato, 215614

TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE

EHA Library, Richa Manwani, 215615

TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT

EHA Library, Nico Gagelmann, 215616

VENETOCLAX MONOTHERAPY AND COMBINED WITH DEXAMETHASONE AS TARGETED THERAPY FOR RELAPSED/REFRACTORY T(11;14) MULTIPLE MYELOMA

EHA Library, Jonathan L Kaufman, 215617

SUBCUTANEOUS DARATUMUMAB (DARA SC) + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: SAFETY RUN-IN RESULTS OF ANDROMEDA

EHA Library, GIAMPAOLO MERLINI, 215618

DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES

EHA Library, RAFAEL ALONSO FERNÁNDEZ, 215619

PREDICTORS OF HEMATOLOGIC AND ORGAN RESPONSE IN AL AMYLOIDOSIS

EHA Library, Giovanni Palladini, 215620

IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Heinz Ludwig, 215621

SELINEXOR COMBINED WITH LOW DOSE BORTEZOMIB AND DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Nizar Bahlis, 215622

THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS

EHA Library, Tobias Klausen, 215623

COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA

EHA Library, Austin Jacobsen, 215624

QUALITY OF HEMATOLOGIC RESPONSE BUT NOT DEPTH OF NT-PROBNP RESPONSE IMPROVES SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS WHO ACHIEVE CARDIAC RESPONSE

EHA Library, Paolo Milani, 215625

SUSTAINED MRD NEGATIVITY AT 12 MONTHS POST-ASCT PREDICTS OUTCOMES FOR MYELOMA PATIENTS: A REAL WORLD STUDY.

EHA Library, Michael Austin, 215626

MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).

EHA Library, Alexis Caulier, 215627

AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).

EHA Library, Michaela Kotrová, 215628

A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

EHA Library, Cristina Gasparetto, 215629

A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME

EHA Library, MERAL BEKSAC, 215630

AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE


EHA Library, ANGELO BELOTTI, 215631

COMPARABLE OUTCOMES USING PROPYLENE GLYCOL-FREE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

EHA Library, Kevin Miller, 215632

ACTIVITY AND SAFETY OF DARATUMUMAB MONOTHERAY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA REQUIRING DIALYSIS: PRELIMINARY RESULTS OF A SPANISH, RETROSPECTIVE, MULTICENTER TRIAL

EHA Library, Maria Jose cejalvo, 215633

OPTIMISING TREATMENT FOR HIGH-RISK MYELOMA IN A STRATIFIED MULTI-CENTRE TRIAL: EXPERIENCE FROM MUKNINE OPTIMUM STUDY

EHA Library, Martin Kaiser, 215634

ASYMPTOMATIC HEART INVOLVEMENT IN AL AMYLOIDOSIS

EHA Library, Marco Basset, 215635

RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS

EHA Library, Dorothy Romanus, 215636

PHARMACOKINETIC EVALUATION OF TEST DOSE PREDICTIONS OF HIGH DOSE MELPHALAN EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA.

EHA Library, Judith Trotman, 215637

A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL

EHA Library, Annemiek Broijl, 215638

LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Qaiser Bashir, 215639

THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY

EHA Library, Wuhan Hui, 215640

IMPACT OF MOLECULAR ANALYSIS ON PROGNOSTIC SCORES IN ESSENTIAL THROMBOCYTHEMIA: A SINGLE CENTER PROSPECTIVE COHORT EXPERIENCE

EHA Library, Damien Luque Paz, 215641

THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Kira Behrens, 215642

BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN

EHA Library, Marito Araki, 215643

PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jaqueline Fernandes, 215644

IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES

EHA Library, Lucia Catani, 215645

POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS

EHA Library, Manuela Mancini, 215646

NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS

EHA Library, Alfio Bonanno, 215647

POSSIBLE SOMATIC MOSAICISM OF THE JAK2 GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Naoki Mori, 215648

MULTICENTER SURVEY ON MANAGEMENT AND OUTCOME OF A RARE HEMATOLOGIC DISEASE: ADULT ONSET HISTIOCYTOSES.

EHA Library, Davide Lazzarotto, 215649

IS ANEMIA THE MAIN SURVIVAL MARKER IN PATIENTS WITH MYELOFIBROSIS IN THE RUXOLITINIB ERA?

EHA Library, María Isabel Montero, 215650

DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY)

EHA Library, Elena Maria Elli, 215651

MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES.

EHA Library, Abhishek Mangaonkar, 215652

ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Marko Lucijanic, 215653

LONG-TERM OUTCOME OF PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE

EHA Library, Danijela Lekovic, 215654

GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT

EHA Library, Daniela Barraco, 215655

TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS

EHA Library, Georgia Metzgeroth, 215656

MANAGEMENT AND OUTCOME OF 25 PREGNANCIES IN WOMEN WITH POLYCYTHAEMIA VERA

EHA Library, Irene Bertozzi, 215657

PEGYLATED INTERFERON ALPHA-2B VERSUS ΑLPHA-2A FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: EFFICACY AND SAFETY PROFILE.

EHA Library, Novella Pugliese, 215658

LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Yoshinori Hashimoto, 215659

SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).

EHA Library, Sarah Wharin, 215660

FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES

EHA Library, Margherita MAFFIOLI, 215661

THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION

EHA Library, Natalia Curto-Garcia, 215662

MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY

EHA Library, Caroline Mcnamara, 215663

JAK2 ALLELIC RATIO PREDICT HIGHER TROMBOTIC RISK IN MYELOFIBROSIS PATIENTS. A SINGLE CENTER EXPERIENCE ON 143 PATIENTS.

EHA Library, Mirko Farina, 215664

RUXOLITINIB AND HYDROXYUREA COMBINATION FOR THE TREATMENT OF MYELOFIBROSIS

EHA Library, Novella Pugliese, 215665

THE “MYMPN” PATIENT REGISTRY: VALIDATION OF A PROSPECTIVE MYELOPROLIFERATIVE NEOPLASM PATIENT REGISTRY

EHA Library, Robyn Scheber, 215666

THE RELATIONSHIP OF BODY MASS INDEX TO SYMPTOM BURDEN IN THE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Robyn Scheber, 215667

MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE

EHA Library, Giulia Bogoni, 215668

RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE IN ENGLAND, NORTHERN IRELAND AND WALES

EHA Library, James Russell, 215669

TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ‘REAL-WORLD’ COHORT STUDY

EHA Library, Peter Westerweel, 215670

PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS

EHA Library, Bozena Sokolowska, 215671

SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS

EHA Library, Telma Nascimento, 215672

CORRELATIONS BETWEEN GENETIC AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Liubov Poluskina, 215673

MUTATIONAL PROFILES OF CLASSIC MYELOPROLIFERATIVE NEOPLASMS IN TAIWANESE PATIENTS: FREQUENCY AND CLINICAL CORRELATION

EHA Library, Huan-Chau Lin, 215674

SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE

EHA Library, Nathalie Faumont, 215676

MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA

EHA Library, Daniela Steinbrecher, 215677

CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.

EHA Library, Vincent Allain, 215678

THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Ioanna Xagoraris, 215679

DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2

EHA Library, Junya Kuroda, 215680

INTEGRATIVE GENOME-WIDE ANALYSIS REVEALS REGULATION OF CELL PROLIFERATION INVOLVING MULTIPLE SIGNALING PATHWAYS BY BRD4-BINDING TARGET GENES IN MANTLE CELL LYMPHOMA CELL LINES.

EHA Library, Taku Tsukamoto, 215681

TRANSCRIPTOME SEQUENCING IN DIFFUSE LARGE B-CELL LYMPHOMA - RIBOSOME BIOGENESIS AND DYSREGULATION OF THE ACTIN CYTOSKELETON ARE ASSOCIATED WITH IMMUNOCHEMOTHERAPY RESISTANCE

EHA Library, Mimmie Stern, 215682

PD1-TIM3+ CELLS ARE THE PREDOMINANT POPULATION OF EXHAUSTED CD8+ CELLS IN FOLLICULAR LYMPHOMA WITH HIGH REACTIVATION POTENTIAL

EHA Library, Theodora Anagnostou, 215683

ENZYME-FREE DIGITAL COUNTING OF ENDOGENOUS CIRCULAR RNA MOLECULES IN FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FROM PATIENTS WITH B-CELL MALIGNANCIES

EHA Library, Mette Dahl, 215684

PROTEIN KINASE CK1 ΑLPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS

EHA Library, Sabrina Manni, 215685

WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION

EHA Library, Mathilde de Jong, 215686

INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS

EHA Library, Jose Tomas Navarro, 215687

NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT’S LYMPHOMA CELLS

EHA Library, Jianda Hu, 215688